Abstract: This invention relates to novel lactams having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
Abstract: This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
Type:
Application
Filed:
November 10, 2009
Publication date:
March 18, 2010
Applicant:
BRISTOL-MYERS SQUIBB PHARMA COMPANY
Inventors:
Qi Han, Hong Liu, Richard E. Olson, Michael G. Yang
Abstract: Corticotropin releasing factor (CRF) antagonists of formula I or II: and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.
Type:
Grant
Filed:
June 29, 2006
Date of Patent:
March 16, 2010
Assignee:
Bristol-Myers Squibb Pharma Company
Inventors:
Liqi He, Paul Gilligan, Robert Chorvat, Argyrios Georgios Arvanitis
Abstract: This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
Type:
Application
Filed:
September 22, 2009
Publication date:
March 4, 2010
Applicant:
BRISTOL-MYERS SQUIBB PHARMA COMPANY
Inventors:
Qi Han, Hong Liu, Richard E. Olson, Michael G. Yang
Abstract: This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
Type:
Application
Filed:
September 17, 2009
Publication date:
February 25, 2010
Applicant:
BRISTOL-MYERS SQUIBB PHARMA COMPANY
Inventors:
Qi HAN, Hong Liu, Richard E. Olson, Michael G. Yang
Abstract: Corticotropin releasing factor (CRF) antagonists of Formula (I): and its use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.
Abstract: This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
Type:
Grant
Filed:
February 19, 2009
Date of Patent:
February 2, 2010
Assignee:
Bristol-Myers Squibb Pharma Company
Inventors:
Qi Han, Hong Liu, Richard E. Olson, Michael G. Yang
Abstract: This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
Type:
Application
Filed:
September 15, 2009
Publication date:
January 14, 2010
Applicant:
BRISTOL-MYERS SQUIBB PHARMA COMPANY
Inventors:
Qi HAN, Hong Liu, Richard E. Olson, Michael G. Yang
Abstract: This invention relates to novel cyclic malonamides having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
Abstract: The invention described herein relates to methods and compositions useful in the diagnosis, treatment and management of cancers that express particular genes, including the moesin, caveolin 1, and/or yes-associated protein 1 genes.
Type:
Application
Filed:
November 10, 2006
Publication date:
July 2, 2009
Applicants:
Bristol-Myers Squibb Pharma Company, The Regents of the University of California
Inventors:
Richard S. Finn, Judy Dering, Dennis J. Slamon, Charles L. Ginther, Edwin A. Clark
Abstract: Field of the Invention This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
Type:
Application
Filed:
February 19, 2009
Publication date:
July 2, 2009
Applicant:
BRISTOL-MYERS SQUIBB PHARMA COMPANY
Inventors:
Qi Han, Hong Liu, Richard E. Olson, Michael G. Yang
Abstract: This invention relates to novel cyclic malonamides having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
Abstract: This invention relates to novel lactams having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
Type:
Application
Filed:
September 9, 2008
Publication date:
April 30, 2009
Applicant:
BRISTOL-MYERS SQUIBB PHARMA COMPANY
Inventors:
Richard E. Olson, Hong Liu, Lorin A. Thompson
Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
Abstract: This invention relates to novel lactams having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
Type:
Grant
Filed:
December 4, 2007
Date of Patent:
March 24, 2009
Assignee:
Bristol-Myers Squibb Pharma Company
Inventors:
Richard E. Olson, Thomas P. Maduskuie, Lorin Andrew Thompson
Abstract: This invention relates to novel lactams having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
Abstract: This invention relates to novel lactams having the Formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
Abstract: This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
Type:
Grant
Filed:
April 19, 2007
Date of Patent:
March 3, 2009
Assignee:
Bristol-Myers Squibb Pharma Company
Inventors:
Qi Han, Hong Liu, Richard E. Olson, Michael G. Yang
Abstract: This invention relates to novel lactams having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
Type:
Application
Filed:
December 4, 2007
Publication date:
November 27, 2008
Applicant:
BRISTOL-MYERS SQUIBB PHARMA COMPANY
Inventors:
Richard E. Olson, Thomas P. Maduskuie, Lorin Andrew Thompson
Abstract: This invention relates to novel lactams having the Formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.